Pharsight

Drugs that contain Omidenepag Isopropyl

1. Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648097 VISIOX PHARMA Pyridylaminoacetic acid compound
Oct, 2029

(5 years from now)

US10774072 VISIOX PHARMA Crystal of N-substituted sulfonamide compound
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 VISIOX PHARMA Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(5 years from now)

US10179127 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US9415038 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

USRE48183 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11197849 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10765750 VISIOX PHARMA Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11793798 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10702511 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11666563 VISIOX PHARMA Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2027

NCE-1 date: 22 September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents